- Home
- ALZN vs DSS Comparison
ALZN vs DSS Comparison
Compare ALZN & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- DSS
- Stock Information
- Founded
- ALZN 2016
- DSS 1984
- Country
- ALZN United States
- DSS United States
- Employees
- ALZN N/A
- DSS N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- DSS Containers/Packaging
- Sector
- ALZN Health Care
- DSS Consumer Discretionary
- Exchange
- ALZN Nasdaq
- DSS Nasdaq
- Market Cap
- ALZN 6.1M
- DSS 7.3M
- IPO Year
- ALZN 2021
- DSS N/A
- Fundamental
- Price
- ALZN $0.96
- DSS $0.94
- Analyst Decision
- ALZN Strong Buy
- DSS
- Analyst Count
- ALZN 1
- DSS 0
- Target Price
- ALZN $32.00
- DSS N/A
- AVG Volume (30 Days)
- ALZN 825.5K
- DSS 17.2K
- Earning Date
- ALZN 03-24-2025
- DSS 03-26-2025
- Dividend Yield
- ALZN N/A
- DSS N/A
- EPS Growth
- ALZN N/A
- DSS N/A
- EPS
- ALZN N/A
- DSS N/A
- Revenue
- ALZN N/A
- DSS $25,019,000.00
- Revenue This Year
- ALZN N/A
- DSS N/A
- Revenue Next Year
- ALZN N/A
- DSS N/A
- P/E Ratio
- ALZN N/A
- DSS N/A
- Revenue Growth
- ALZN N/A
- DSS N/A
- 52 Week Low
- ALZN $0.92
- DSS $0.77
- 52 Week High
- ALZN $15.06
- DSS $2.30
- Technical
- Relative Strength Index (RSI)
- ALZN 26.54
- DSS 55.12
- Support Level
- ALZN $0.92
- DSS $0.90
- Resistance Level
- ALZN $1.15
- DSS $0.96
- Average True Range (ATR)
- ALZN 0.06
- DSS 0.06
- MACD
- ALZN -0.01
- DSS 0.01
- Stochastic Oscillator
- ALZN 13.61
- DSS 76.96
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia.